Investment Ratings
As per analysts rating in the last 6 months, the recommendation is to HOLD Mangalam Drugs
-
Master Rating:
-
Mangalam Drugs & Orgs. has an operating revenue of Rs. 398.45 Cr. on a trailing 12-month basis. An annual revenue growth of 36% is outstanding, Pre-tax margin of 10% is healthy, ROE of 21% is exceptional. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 11 which is a POOR score indicating inconsistency in earnings, a RS Rating of 11 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Mangalam Drugs and Organics Ltd Forecast
Price Estimates
Eps And Sales Estimates
Mangalam Drugs and Organics Ltd Synopsis
NSE-Medical-Generic Drugs
Mangalam Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 380.14 Cr. and Equity Capital is Rs. 15.83 Cr. for the Year ended 31/03/2021. Mangalam Drugs and Organics Ltd. is a Public Limited Listed company incorporated on 18/04/1972 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1972PLC116413 and registration number is 116413.-
Market Cap
INR 199.43 Cr
-
Sales
INR 398.45 Cr
-
Shares in Float
0.78 Cr
-
No of Funds
4 K
-
Yield
0.68%
-
Book Value
1.5
-
U/D Vol Ratio
1.1
-
LTDebt/Equity
5%
-
Alpha
-0.09
-
Beta
0.74
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 50.53% | 50.53% | 50.53% |
| Foreign Portfolio Investors | 0% | 0% | 0% |
| Financial Institutions/ Banks | 0.01% | 0.01% | 0.01% |
| Individual Investors | 42.69% | 44.28% | 44.01% |
| Others | 6.77% | 5.18% | 5.45% |
| Name | Designation |
|---|---|
| Mr. Govardhan M Dhoot | Chairman & Managing Director |
| Mr. Brijmohan M Dhoot | Executive Director |
| Mr. Ajay R Dhoot | Non Executive Director |
| Mr. Aaditya R Dhoot | Non Executive Director |
| Mr. Subhash C Khattar | Independent Director |
| Mr. Rukmesh Dhandhania | Independent Director |
| Mrs. Nidhi Mundada | Independent Director |
| Mr. Prashant J Pandit | Independent Director |
Mangalam Drugs and Organics Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 114.2019 | 104.7784 | 90.787 | 88.6873 | 97.0257 |
| Operating Expenses Qtr Cr | 109.2615 | 94.4298 | 81.3286 | 76.084 | 79.4048 |
| Operating Profit Qtr Cr | 4.9404 | 10.3486 | 9.4584 | 12.6033 | 17.6209 |
| Depreciation Qtr Cr | 2.5009 | 2.3899 | 2.5153 | 2.3336 | 2.2654 |
| Interest Qtr Cr | 2.9779 | 2.9626 | 2.2157 | 2.3482 | 2.6042 |
| Tax Qtr Cr | 3.7549 | 1.1027 | 4.687 | 2.7551 | 2.3485 |
| Net Profit Qtr Cr | 4.5281 | 4.4157 | 2.1542 | 6.4342 | 11.087 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 384.8612 | 283.5348 | 227.8965 | 280.2066 | 303.1935 |
| Operating Expenses Annual Cr | 326.8407 | 258.6602 | 217.8985 | 232.5111 | 256.9692 |
| Operating Profit Annual in Cr | 53.2999 | 23.6934 | 9.6812 | 46.8685 | 45.9164 |
| Depreciation Cr | 9.1753 | 8.2178 | 7.0885 | 6.5682 | 5.0071 |
| Interest Annual Cr | 9.3261 | 10.4047 | 8.6465 | 11.78 | 10.0365 |
| Tax Annual Cr | 11.5482 | -2.0004 | 2.2938 | 9.4577 | 8.9057 |
| Net Profit Annual Cr | 27.9709 | 8.2525 | -8.0308 | 19.8896 | 22.275 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | 30.5471 | 21.6927 | 24.5763 | 42.7988 | |
| Cash from Investing Activity Annual Cr | -6.8726 | -9.2559 | -15.9549 | -39.4467 | |
| Cash from Financing Annual Activity Cr | -23.4788 | -11.4337 | -8.8183 | -3.2201 | |
| Net Cash Flow Annual Cr | 0.1957 | 1.0031 | -0.1969 | 0.132 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 130.9619 | 103.9387 | 95.6631 | 103.7665 | 85.7172 |
| Fixed Assets Annual Cr | 118.435 | 102.3095 | 103.6914 | 101.9805 | 92.5562 |
| Total Non Current Assets Annual Cr | 130.8706 | 111.4923 | 106.3153 | 103.9459 | 93.7189 |
| Total Current Assets Annual Cr | 131.9771 | 119.1748 | 105.0396 | 122.8415 | 95.7849 |
| Total Assets Annual Cr | 262.8477 | 230.6671 | 211.3549 | 226.7874 | 189.5038 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 65.666 | 60.438 | 65.557 | 54.154 | |
| ROE Annual % | 7.93 | -8.39 | 19.16 | 25.98 | |
| ROCE Annual % | 13.74 | 2.41 | 32.39 | 36.88 | |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | 15.26 | 8.8 | 4.39 | 17.07 | 15.26 |
Mangalam Drugs and Organics Ltd Technicals
EMA & SMA
CURRENT PRICE
124.05 
(0.04)
-
- Bullish Moving Averages 1
- Bearish Moving Averages 15
EMA
-
20 Day
129.45
-
50 Day
136.24
-
100 Day
139.4
-
200 Day
137.78
Mangalam Drugs and Organics Ltd Resistance and support
124.45 PIVOT
-
First Resistance
125.5
-
Second Resistance
127
-
Third Resistance
128.06
-
First Support
122.95
-
Second Support
121.9
-
Third Support
120.4
-
RSI
35.64
-
MFI
12.84
-
MACD
-4.44
-
MACD signal line
-4.1
Mangalam Drugs and Organics Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 15,744 | 940,861 | 59.76% |
| Week | 39,685 | 2,183,855 | 55.03% |
| 1 Month | 41,414 | 2,440,965 | 58.94% |
| 6 Month | 188,710 | 8,656,112 | 45.87% |
Mangalam Drugs and Organics Ltd Price change analysis
-10.75
Over 1 month
Low High 117.55 148
-22.15
Over 3 month
Low High 117.55 157.5
-11.45
Over 6 months
Low High 117.55 196.95
-23.2
Over Year
Low High 91 196.95Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Ipca Laboratories Ltd | 2,767.10 | 2,028.10 (-2.08%) | 14471 |
| Wockhardt Ltd | 804.50 | 441.75 (2.47%) | 67565 |
| Shilpa Medicare Ltd | 670.95 | 563.85 (0.23%) | 12578 |
| Dr Reddys Laboratories Ltd | 5,613.65 | 4,592.10 (-1.51%) | 11227 |
News
Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More
Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read More
Mangalam Drugs & Organics Ltd - 532637 - Standalone Un-Audit
Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (th Read More
MANGALAM DRUGS & ORGANICS LTD. - 532637 - Board Meeting Outc
Pursuant to Regulation 30 read with part A of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (th Read More
Mangalam Drugs & Organics Ltd - 532637 - Disclosures under R
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2 Read MoreBlogs